{
    "nctId": "NCT02362230",
    "briefTitle": "Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy",
    "officialTitle": "Sun Yat-sen University Cancer Center",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years or older\n* ECOG 0 or 1\n* Primary or metastatic tumor onfirmed as triple negative\n* Measurable disease per RECIST version 1.1\n* normal organ function, including bone marrow function, renal function, liver function, and cardiac function\n* Two or more prior chemotherapy\n* signed and dated an informed consent form\n* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Pregnant or breast feeding\n* ECOG score \u22672\n* Uncontrolled medical problems\n* Hepatic, renal, or bone marrow dysfunction as detailed above\n* Concurrent malignancy or history of other malignancy within the last five years except as noted above\n* Patients were unable or unwilling to comply with program requirements",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}